|
|
|
|
|
|
Sponsored by: |
Genentech |
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00406965 |
This is a Phase II, multicenter, randomized, double blind, placebo controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of subcutaneously administered HAE1 in subjects 12-75 years old with moderate to severe asthma whose symptoms are inadequately controlled with moderate to high-dose ICS and LABA.
Condition | Intervention | Phase |
Allergic Asthma |
Drug: HAE1 (PRO98498) |
Phase II |
MedlinePlus related topics: | Asthma |
ChemIDplus related topics: | Proline |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of HAE1 (PRO98498) in Subjects With Moderate to Severe Allergic Asthma |
Estimated Enrollment: | 50 |
Study Start Date: | December 2006 |
Study Completion Date: | September 2007 |
Ages Eligible for Study: | 12 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | HAE3973g |
First Received: | November 30, 2006 |
Last Updated: | December 31, 2007 |
ClinicalTrials.gov Identifier: | NCT00406965 |
Health Authority: | United States: Food and Drug Administration |
|
|
|